20 assets in Kidney Failure

Therapeutic assets addressing Kidney Failure, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Normal Human Serum Albumin Kidney Failure	Anna Cruceta	P4	BBB (72)
Dexasone Kidney Failure	Augusta University	P3	BB (70)
Bortezomib Kidney Failure	Augusta University	P2	BB (65)
Empagliflozin Kidney Failure	University Hospital, Basel, Switzerland	P4	BB (65)
Envarsus Product Kidney Failure	University of Alberta	P4	BB (65)
Cyclophosphamide Kidney Failure	Augusta University	P2	B (63)
Lenalidomide Kidney Failure	Hellenic Society of Hematology	P2	B (62)
Pomalidomide Kidney Failure	Hellenic Society of Hematology	P2	B (60)
Isatuximab Kidney Failure	Hellenic Society of Hematology	P2	CCC (53)
Ranitidine Kidney Failure	Hellenic Society of Hematology	P2	CCC (53)
Diphenhydramine Kidney Failure	Hellenic Society of Hematology	P2	CCC (52)
bay2395840 Kidney Failure	Bayer	P1	CC (43)
Carboplatin Kidney Failure	National Cancer Institute (NCI)	P1	CC (43)
Osivelotor Kidney Failure	Pfizer	P1	CC (43)
Veliparib Kidney Failure	National Cancer Institute (NCI)	P1	CC (43)
Daratumumab-Hyaluronidase Kidney Failure	Augusta University	Early P1	C (39)
Byetta Kidney Failure	Rigshospitalet, Denmark	N/A	D (30)
Exenatide Kidney Failure	Rigshospitalet, Denmark	N/A	D (30)
Oxygen Kidney Failure	Rigshospitalet, Denmark	N/A	D (30)
Opemalirsen Kidney Failure	AstraZeneca	P1	NR ()